



PATENT

Case Docket No. CVGENG.008CP1

Date: October 8, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Stegmann, et al.
Appl. No. : 10/649,480
Filed : August 27, 2003
For : METHOD OF PRODUCING
BIOLOGICALLY ACTIVE
HUMAN ACIDIC FIBROBLAST
GROWTH FACTOR AND ITS
USE IN PROMOTING
ANGIOGENESIS
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 8, 2003

(Date)

Che S. Chereskin

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) A Supplemental Information Disclosure Statement.
- (X) A PTO Form 1449 with eight (8) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Che S. Chereskin


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicant : Stegmann, et al.
App. No. : 10/649,480
Filed : August 27, 2003
For : METHOD OF PRODUCING BIOLOGICALLY
ACTIVE HUMAN ACIDIC FIBROBLAST GROWTH
FACTOR AND ITS USE IN PROMOTING
ANGIOGENESIS
Examiner : Unknown
Group Art Unit : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 8 references which are also enclosed.

This Information Disclosure Statement is being filed within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct. 8, 2003

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CVGENG.008CP1APPLICATION NO.
10/649,480SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Stegmann, et al.FILING DATE
August 27, 2003GROUP
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	Hendel, et al. "Effect of Intracoronary Recombinant Human Vascular Endothelial Growth Factor on Myocardial Perfusion," <i>Circulation</i> , Vol. 101, pp. 118-121, 2000.
	Laham, et al. "Subxyphoid Access of the Normal Pericardium: A Novel Drug Delivery Technique," <i>Catheterization and Cardiovascular Interventions</i> , Vol. 47, pp. 109-111, 1999.
	Laham, et al. "Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery, Results of a Phase I Randomized, Double-Blind, Placebo-Controlled Trial," <i>Circulation</i> , Vol. 100, pp. 1865-1871, 1999.
	Rosengart, et al. "Angiogenesis Gene Therapy, Phase I Assessment of Direct Intramyocardial Administration of an Adenovirus Vector Expressing VEGF121 cDNA to Individuals with Clinically Significant Severe Coronary Artery Disease," <i>Circulation</i> , Vol. 100, pp. 468-474, 1999.
	Stegmann, et al. "First Angiogenic Treatment of Coronary heart Disease by FGF-1: Long-Term Results After 3 years," <i>Cardiac and Vascular Regeneration</i> , Vol. 1, No. 1, pp. 5-10, March, 2000.
	Symes, et al. "Gene Therapy with Vascular Endothelial Growth Factor for Inoperable Coronary Artery Disease," <i>Annals of Thoracic Surgery</i> , Vol. 68, pp. 830-837, 1999.
	Udelson, et al. "Therapeutic Angiogenesis with Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients with Severe Symptomatic Chronic Coronary Artery Disease," <i>Circulation</i> , Vol. 102, pp. 1605-1610, 2000.
	Waxman, et al. "Persistent Primary Coronary Dilation Induced by Transatrial Delivery of Nitroglycerin into the Pericardial Space: A Novel Approach for Local Cardiac Drug Delivery," <i>Journal of the American College of Cardiology</i> , Vol. 33, No. 7, pp. 2073-2077, June, 1999.

H:\DOCS\CSC\CSC-5865.DOC
100803

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	